BioTrack Capital

BioTrack Capital is a venture capital firm established in 2017 and located in Shanghai, China. The company focuses on investing in the healthcare and life science sectors, targeting opportunities within China. Its primary goal is to support innovative companies that are advancing developments in these critical industries.

Kevin (Penghui) Chen

Co-Founding Partner

Jiacong Guo

Principal

Feng Tao

Co-Founding Partner

Jingfei Zhang

Principal

63 past transactions

Rona Therapeutics

Series B in 2025
Rona Therapeutics is an innovative RNA therapeutics platform focused on the discovery, development, and commercialization of modular and programmable RNA medicines. The company specializes in oligonucleotide therapies, RNA editing, and polymeric molecules, aiming to create transformative RNA therapies that can significantly impact disease treatment across various therapeutic areas. Rona Therapeutics is committed to developing proprietary technologies that enhance the specificity, stability, and longevity of therapeutic effects. To support its mission, the company is establishing state-of-the-art facilities to advance nucleic acid synthesis, delivery platforms, and RNA biology. Through its efforts, Rona Therapeutics seeks to improve patient health outcomes and foster an environment conducive to innovation and excellence in RNA medicine.

Moyang Biotechnology

Series B in 2024
Moyang Biotechnology specializes in the development and consulting services of medical biomaterials for beauty sector.

Bioyond Tech

Series A in 2024
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

Rona Therapeutics

Series A in 2024
Rona Therapeutics is an innovative RNA therapeutics platform focused on the discovery, development, and commercialization of modular and programmable RNA medicines. The company specializes in oligonucleotide therapies, RNA editing, and polymeric molecules, aiming to create transformative RNA therapies that can significantly impact disease treatment across various therapeutic areas. Rona Therapeutics is committed to developing proprietary technologies that enhance the specificity, stability, and longevity of therapeutic effects. To support its mission, the company is establishing state-of-the-art facilities to advance nucleic acid synthesis, delivery platforms, and RNA biology. Through its efforts, Rona Therapeutics seeks to improve patient health outcomes and foster an environment conducive to innovation and excellence in RNA medicine.

Brise Pharma

Seed Round in 2024
Brise Pharma is a scientific research company specializing in developing novel biopharmaceutical drugs for treating pain. Its primary focus lies in creating innovative and distinct analgesic treatments targeting migraine, neuropathic, and musculoskeletal pain, aiming to provide safe, effective, and accessible pain relief solutions globally.

Shenluo Medical

Series B in 2024
Shenluo Medical manufactures functional neural implantable medical devices.

Yuce Biotechnology

Series B in 2024
Yuce Biotechnology is a high-tech company focused on the industrialization of single-molecule immunodiagnostic technologies.

OnCusp Therapeutics

Series A in 2024
OnCusp Therapeutics is a biopharmaceutical company dedicated to transforming advanced research into innovative cancer treatments. Founded by Bing Yuan, Eric Slosberg, and Andy Fu, the company focuses on accelerating the development of oncology medications to provide help and hope to cancer patients globally. OnCusp Therapeutics specializes in translating preclinical drug candidates into clinical proof-of-concept stages, aiming to swiftly advance these assets into early global clinical development.

Salus BioMed

Series A in 2023
Salus BioMed is a biomedical company focused on advancing genetic sequencing technology and spatial omics products. It specializes in the development of a DNA sequencing platform that enhances the measurement of gene activity through high-definition spatial transcriptomics. This technology supports users in diagnosing and treating various diseases, positioning Salus BioMed at the forefront of innovation in genomic research and healthcare solutions.

Acchrom

Series A in 2023
Acchrom, also known as Huapu Instrument (Beijing) Technology Co., Ltd., is a prominent company specializing in chromatography, offering comprehensive solutions that include products, technical services, and support. The company's focus is on chromatographic separation products designed to effectively separate mixtures. Acchrom emphasizes a closed-loop system that integrates chromatography equipment, consumables, software, and customer services, thereby enabling clients to conduct chromatographic separation analysis efficiently. The company is dedicated to establishing itself as a well-known national brand in chromatography and has developed targeted marketing strategies and a professional sales team across key provinces to enhance its marketing network and presence in the industry.

Reforgene Medicine

Series B in 2023
Reforgene Medicine is a biomedical company focused on developing innovative drugs aimed at curing genetic diseases, chronic illnesses, and cancer. Utilizing advanced gene editing and genomic technologies, the company creates programmable medicine that offers targeted treatments for patients. By harnessing the potential of genome editing, Reforgene Medicine seeks to improve patient outcomes and contribute to the advancement of personalized healthcare solutions.

Bioyond Tech

Series A in 2023
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

Qitan Technology

Series C in 2022
Chengdu Qitan Technology Co., Ltd. specializes in the development and manufacture of advanced gene sequencing instruments utilizing nanopore technology. Founded in 2016 and based in Chengdu, China, the company offers a fourth generation gene sequencer that enables single-molecule sequencing with long read lengths and real-time output. This innovative technology is designed to serve various sectors, including biopharmaceuticals, healthcare, and agriculture, facilitating applications such as immunophenotyping, pathogen detection, analysis of intestinal flora, and tumor genome detection. Qitan Tech's solutions are notable for their cost-effectiveness and simplicity, as they do not require complicated library preparation, thus enhancing the accessibility of gene sequencing for cutting-edge biological research and clinical diagnostics.

Wangli Technology

Venture Round in 2022
Wangli Technology is a digital therapy technology platform for mental illness focusing on exploring the field of human brain and spirit.

BestCovered

Series A in 2022
BestCovered is a company focused on developing digital screening tools aimed at early detection and intervention for Alzheimer's disease. By leveraging artificial intelligence technologies, including speech analysis, gesture recognition, and natural language processing, BestCovered creates cognitive impairment risk assessment tools. These tools enable hospitals to achieve high prediction accuracy for Alzheimer's, facilitating timely care for patients. Additionally, BestCovered offers systematic multi-dimensional activation courses designed to help individuals maintain a flexible mind, further contributing to cognitive health and well-being.

Acchrom

Angel Round in 2022
Acchrom, also known as Huapu Instrument (Beijing) Technology Co., Ltd., is a prominent company specializing in chromatography, offering comprehensive solutions that include products, technical services, and support. The company's focus is on chromatographic separation products designed to effectively separate mixtures. Acchrom emphasizes a closed-loop system that integrates chromatography equipment, consumables, software, and customer services, thereby enabling clients to conduct chromatographic separation analysis efficiently. The company is dedicated to establishing itself as a well-known national brand in chromatography and has developed targeted marketing strategies and a professional sales team across key provinces to enhance its marketing network and presence in the industry.

Huili Bio

Series A in 2022
Huili Bio is a next-generation synthetic biology enzyme computational design platform.

BANGBANG ROBOT

Series B in 2022
Shanghai BangBang Robot Co., Ltd. is a high-tech company established in 2016 that specializes in the research, development, production, and sales of intelligent assistant products. Based in Shanghai, the company focuses on creating robotic devices aimed at providing travel assistance. Its product offerings include rehabilitation training robots, life assistance robots, and intelligent electric scooters, all designed to enhance mobility and independence for disabled individuals. By integrating advanced technology into its products, BangBang Robot aims to enable users to travel freely and improve their quality of life.

NuProbe

Series B in 2022
NuProbe, Inc. is a genomics and molecular diagnostics company that specializes in noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative polymerase chain reaction (qPCR) mutation detection. The company's innovative probe technology facilitates a Sample-In Answer-Out (SIAO) solution, integrating cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretations. This precision diagnostic technology is designed for the early detection of cancer and infectious diseases, offering high sensitivity and the ability to capture disease signatures comprehensively. As a result, healthcare specialists are empowered to act swiftly, enabling timely treatment for patients.

Rigen Biotech

Venture Round in 2022
Rijing Biosciences has launched thyroid biopsy needles, multi-gene qPCR detection and NGS detection, Thyroscan® thyroid nodule benign and malignant classifier, and targeted surgery for thyroid cancer from preoperative sampling, diagnosis, to postoperative monitoring. Full-process series products such as post-recurrence monitoring provide a variety of solutions for the entire thyroid cancer diagnosis and treatment cycle.

LMBio

Seed Round in 2022
Medical

DeepKinase

Series A in 2022
DeepKinase is a biotechnology company that specializes in clinical proteomics, focusing on the diagnosis of tumor, immune, and neurodegenerative diseases. The company leverages its proprietary Deep Omics of Tyrosine Kinase (DoTK) platform, which is based on patented proteomics technology. By utilizing advanced proteomics techniques, DeepKinase aims to provide more accurate and precise diagnostic solutions for complex diseases, enhancing the understanding and treatment options available for patients. Through its innovative approach, the company seeks to advance the field of proteomics and improve clinical outcomes.

TopOlefin Technology

Series A in 2022
TopOlefin Technology specializes in the research, development, and production of advanced polymer materials, with a focus on high-end optical resins. The company is dedicated to creating products characterized by high transparency, high refractive index, and strong gas barrier properties. These innovative materials find applications across various industries, including optical lenses, medical packaging, and consumer packaging. By prioritizing green and intelligent design, TopOlefin Technology aims to deliver high-quality resin solutions that meet the diverse needs of its clients.

Hesguard

Seed Round in 2021
Hesguard is a medical device developer and producer of high-end implantable medical devices related to ophthalmic diseases.

Yuanjian Youke

Series A in 2021
Yuanjian Youke is an integrated CDMO service provider for cell and gene therapy industry.

Cargene

Seed Round in 2021
Founded in 2020, Cargene Biopharma is a preclinical-stage biopharmaceutical company developing innovative oligonucleotide therapeutics for liver fibrosis and ophthalmic disorders, with operations in Singapore, USA and China. Cargene uses proprietary platforms backed by novel biology and chemistry insights, Cargene aims to improve quality of life for millions of patients worldwide through creating highly specific, stable and potent nucleic acid-based medicines for the treatment of a broad range of diseases.

Mobile Vision Network Technology

Seed Round in 2021
Move Vision Technology is a digital therapy and smart wearable device platform company. The company focuses on the full-cycle health management of cardiovascular diseases. As a technologically innovative enterprise in the field of cardiovascular health for life monitoring and digital therapy, the goal is to apply digital therapy in-depth in the early warning, monitoring and rehabilitation management of cardiovascular diseases. Through the interdisciplinary combination of clinical medicine, biomedical engineering, bioinformatics, etc., the research and development of multi-field software and hardware products will be completed.

Carcell BioPharma

Seed Round in 2021
Carcell BioPharma is a pre-clinical biotechnology company focused on developing innovative cell and gene therapy products. The company specializes in biopharmaceutical platforms aimed at advancing next-generation therapies, particularly through engineered red blood cells for immune regulation and non-viral vector gene delivery utilizing lipid nanoparticles. Carcell BioPharma's unique cross-border business model supports its commitment to accelerating the discovery and development of these cutting-edge therapies, addressing critical needs in the field of medicine.

Brise Pharma

Angel Round in 2021
Brise Pharma is a scientific research company specializing in developing novel biopharmaceutical drugs for treating pain. Its primary focus lies in creating innovative and distinct analgesic treatments targeting migraine, neuropathic, and musculoskeletal pain, aiming to provide safe, effective, and accessible pain relief solutions globally.

Reforgene Medicine

Series A in 2021
Reforgene Medicine is a biomedical company focused on developing innovative drugs aimed at curing genetic diseases, chronic illnesses, and cancer. Utilizing advanced gene editing and genomic technologies, the company creates programmable medicine that offers targeted treatments for patients. By harnessing the potential of genome editing, Reforgene Medicine seeks to improve patient outcomes and contribute to the advancement of personalized healthcare solutions.

CytoLynx Therapeutics

Funding Round in 2021
CytoLynx Therapeutics is a R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline.

HC Scientific

Series B in 2021
HC Scientific (Chengdu) L.L.C., established in 2016, is a national high-tech enterprise focused on developing intelligent solutions in life technology. The company aims to empower life sciences through innovative products, including genetic testing instruments, reagents, and software, primarily used in clinical molecular diagnostics, health gene testing, and agricultural molecular breeding. HC Scientific is committed to autonomous research and development of intellectual property and is recognized for its contributions to China's new economy development initiatives. The organization employs a team of experts, including returning PhDs and professors, who have developed advanced life science technology platforms. Through its diverse product pipeline, HC Scientific streamlines complex tasks for practitioners in the life science field, thereby creating substantial value for its partners and contributing to significant national and provincial scientific and technological projects.

Tendfo

Series A in 2021
Tendfo is a company focused on developing and manufacturing innovative medical devices specifically for interventional therapy related to pulmonary embolism. The firm is dedicated to research and development, as well as the production and sale of high-end medical devices aimed at venous vascular intervention. In addition to its core product offerings, Tendfo provides technology development, technical consultation, and technical services within the medical device sector. The company also engages in the import and export of medical device goods and technologies, ensuring that it meets the needs of healthcare providers while maintaining a commitment to quality and cost-effectiveness.

Qitan Technology

Series B in 2021
Chengdu Qitan Technology Co., Ltd. specializes in the development and manufacture of advanced gene sequencing instruments utilizing nanopore technology. Founded in 2016 and based in Chengdu, China, the company offers a fourth generation gene sequencer that enables single-molecule sequencing with long read lengths and real-time output. This innovative technology is designed to serve various sectors, including biopharmaceuticals, healthcare, and agriculture, facilitating applications such as immunophenotyping, pathogen detection, analysis of intestinal flora, and tumor genome detection. Qitan Tech's solutions are notable for their cost-effectiveness and simplicity, as they do not require complicated library preparation, thus enhancing the accessibility of gene sequencing for cutting-edge biological research and clinical diagnostics.

Innogen Pharmaceutical

Venture Round in 2021
Innogen Pharmaceutical Technology is an international biopharmaceutical company specializing in the development and manufacturing of innovative drugs. The company utilizes advanced genetic engineering and recombinant protein biopharmaceutical processes to create new therapies. Its primary focus is on addressing the treatment needs of patients suffering from diabetic metabolic diseases and significant central nervous system disorders. Through its research and development efforts, Innogen aims to deliver effective solutions that enhance patient care and improve health outcomes.

EdiGene

Series B in 2021
EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Brattea

Series B in 2021
Brattea is a medical device research and development company specializing in renal denervation products aimed at addressing various health conditions, including hypertension, cancer pain, and diabetes. The company develops interventional devices that include renal artery ablation catheters, radiofrequency ablation equipment, and medical mapping systems. These products are designed to treat a range of medical issues, such as refractory hypertension, obstructive sleep apnea, kidney disease, and heart failure. Through its innovative approach, Brattea aims to provide reliable solutions that improve patient outcomes and enhance the quality of care in the medical field.

OnCusp Therapeutics

Seed Round in 2021
OnCusp Therapeutics is a biopharmaceutical company dedicated to transforming advanced research into innovative cancer treatments. Founded by Bing Yuan, Eric Slosberg, and Andy Fu, the company focuses on accelerating the development of oncology medications to provide help and hope to cancer patients globally. OnCusp Therapeutics specializes in translating preclinical drug candidates into clinical proof-of-concept stages, aiming to swiftly advance these assets into early global clinical development.

NewMed Medical

Series C in 2021
NewMed Medical is a Shanghai-based medical device supplier specializing in interventional artificial heart valve systems. Founded in 2015, the company focuses on researching, developing, manufacturing, and marketing products that include artificial heart valves and transcatheter implantation systems. These products are designed to replace diseased mitral valves, simplifying heart valve replacement surgeries, reducing treatment risks, and enabling faster patient recovery while saving surgery expenses.

Hengmei Foods

Series A in 2021
Hengmei Foods is a group of companies that focuses on the R&D and production of healthy food, snacks, and weight management.

MediTrust Health

Series B in 2021
MediTrust Health is a leading healthcare platform in China that offers a wide range of health insurance products and comprehensive medical services. The company connects pharmaceutical companies, insurers, hospitals, and patients, creating a cohesive ecosystem that benefits all stakeholders involved. By integrating high-quality medical resources with health insurance, MediTrust Health aims to deliver affordable, personalized healthcare solutions to families. In addition to its insurance offerings, the company focuses on improving the management of medical expenses and enhancing patient access to necessary services through innovative payment solutions. MediTrust Health's commitment to addressing the complexities of medical financing and providing diverse healthcare benefits positions it as a significant player in the healthcare industry.

Exegenesis Bio

Series B in 2021
Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

NuProbe

Series B in 2021
NuProbe, Inc. is a genomics and molecular diagnostics company that specializes in noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative polymerase chain reaction (qPCR) mutation detection. The company's innovative probe technology facilitates a Sample-In Answer-Out (SIAO) solution, integrating cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretations. This precision diagnostic technology is designed for the early detection of cancer and infectious diseases, offering high sensitivity and the ability to capture disease signatures comprehensively. As a result, healthcare specialists are empowered to act swiftly, enabling timely treatment for patients.

SeekGene

Series A in 2021
SeekGene is a company specializing in genetic data analysis solutions, particularly in the development and clinical application of single-cell sorting assays. With a team that possesses extensive research and clinical service experience, SeekGene aims to apply single-cell sequencing technology to real-world clinical research effectively. The company has developed a high-throughput single-cell transcriptome sequencing kit that is recognized for its superior performance, flexibility, simplicity, and cost-effectiveness. This innovative kit is designed to facilitate the clinical transformation of single-cell sequencing technology, enabling better understanding of immune responses at the single-cell level. By focusing on technologies related to T cell receptor and peptide-bound major histocompatibility complex pairing, SeekGene supports clinical and drug research as well as disease monitoring and treatment efforts.

Raynovent

Series B in 2020
Raynovent is an innovative biotech company focused on researching and developing new drugs for liver and respiratory diseases. The company aims to create effective treatment therapies for patients suffering from viral and infectious illnesses in these areas. Through its expertise in pharmaceutical biotechnology consulting and technology transfer, Raynovent supports healthcare professionals in diagnosing and treating infectious diseases more effectively.

BioNova Pharma

Series B in 2020
BioNova Pharma biopharmaceutical company that develops and commercializes innovative medicines for cancer and other life-threatening diseases. The company is expanding company with a strong pipeline based on in-house R&D initiatives, partnerships with, and purchases from partners with cutting-edge technology. The goal of BioNova is to close the gap between the high unmet medical needs and the dearth of innovative medicines by developing an innovative R&D platform with a substantial pipeline to address multiple disease areas.

Haihe Biopharma

Series B in 2020
Haihe Biopharma is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative anti-tumor drugs aimed at addressing complex diseases. The company specializes in pharmacological efficacy evaluation and offers a range of products, including novel topoisomerase I inhibitors and oral c-Met highly selective inhibitors. Through its research and development efforts, Haihe Biopharma seeks to enhance health outcomes and the quality of research for its customers, providing effective solutions in the fight against cancer.

CF PharmTech

Series F in 2020
CF PharmTech, Inc. is an independent specialty pharmaceutical company founded in 2007 and headquartered in Suzhou, China. The company specializes in the development and manufacturing of inhalation products, including metered dose inhalers, dry powder inhalers, nasal sprays, and nebulizers. CF PharmTech focuses on creating high-quality and affordable medications for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. In addition to its product development efforts, the company provides contract manufacturing organization (CMO) services, enhancing its capabilities in the global market. With a commitment to effective patient care, CF PharmTech aims to improve management of respiratory conditions through its innovative offerings.

Asieris Pharmaceuticals

Series C in 2020
Asieris Pharmaceuticals Co. Ltd. is a biotechnology company based in Taizhou, China, founded in 2010. The company is dedicated to the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. By focusing on oncology and infectious diseases, Asieris Pharmaceuticals seeks to develop innovative therapies that meet the medical needs of patients both in China and globally.

Ezisurg Medical

Series B in 2020
Ezisurg Medical Co., Ltd. is a Shanghai-based company founded in 2011 that specializes in developing and commercializing minimally invasive surgical products. The company offers a range of devices designed for various medical procedures, including general, bariatric, thoracic, and colorectal surgeries. Its product lineup includes the easyEndo Universal Linear Cutting Stapler, easyCS Circular Stapler, easyLC Linear Cutter Stapler, easyPPH Stapler, and easyUS Ultrasonic Scalpel System. Ezisurg Medical is committed to delivering high-quality and affordable medical technology solutions to hospitals, surgeons, and patients, with a focus on enhancing surgical efficacy and safety through its innovative product offerings.

Yunhu Health

Series A in 2019
Yunhu Health, also known as Hangzhou Yunhu Network Technology Co., Ltd., is a Chinese company established in 2017 that specializes in mobile medical testing services. The company operates a comprehensive platform offering pregnancy, genetic, and male pre-pregnancy chromosome testing, along with various health management services. Utilizing a self-built cold chain logistics system, Yunhu Health efficiently transports inspection samples to laboratories for analysis, ensuring that test results are promptly uploaded to its cloud-based platform. This allows customers to easily access and review their results online. Additionally, the platform provides value-added services such as interpretation of inspection reports and recommendations for disease diagnosis and treatment, enhancing the diagnostic capabilities of primary medical institutions across China.

AccuMedical

Series A in 2019
AccuMedical is a full-line product company in the field of neurological intervention, headquartered in Beijing with an R&D center located in California. It develops and produces medical device products for the treatment of aneurysms, preventing, and treating bleeding diseases caused by the rupture of vascular aneurysms.

Raynovent

Series A in 2019
Raynovent is an innovative biotech company focused on researching and developing new drugs for liver and respiratory diseases. The company aims to create effective treatment therapies for patients suffering from viral and infectious illnesses in these areas. Through its expertise in pharmaceutical biotechnology consulting and technology transfer, Raynovent supports healthcare professionals in diagnosing and treating infectious diseases more effectively.

MediTrust Health

Series A in 2019
MediTrust Health is a leading healthcare platform in China that offers a wide range of health insurance products and comprehensive medical services. The company connects pharmaceutical companies, insurers, hospitals, and patients, creating a cohesive ecosystem that benefits all stakeholders involved. By integrating high-quality medical resources with health insurance, MediTrust Health aims to deliver affordable, personalized healthcare solutions to families. In addition to its insurance offerings, the company focuses on improving the management of medical expenses and enhancing patient access to necessary services through innovative payment solutions. MediTrust Health's commitment to addressing the complexities of medical financing and providing diverse healthcare benefits positions it as a significant player in the healthcare industry.

Yunhu Health

Series A in 2019
Yunhu Health, also known as Hangzhou Yunhu Network Technology Co., Ltd., is a Chinese company established in 2017 that specializes in mobile medical testing services. The company operates a comprehensive platform offering pregnancy, genetic, and male pre-pregnancy chromosome testing, along with various health management services. Utilizing a self-built cold chain logistics system, Yunhu Health efficiently transports inspection samples to laboratories for analysis, ensuring that test results are promptly uploaded to its cloud-based platform. This allows customers to easily access and review their results online. Additionally, the platform provides value-added services such as interpretation of inspection reports and recommendations for disease diagnosis and treatment, enhancing the diagnostic capabilities of primary medical institutions across China.

Haihe Biopharma

Series B in 2019
Haihe Biopharma is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative anti-tumor drugs aimed at addressing complex diseases. The company specializes in pharmacological efficacy evaluation and offers a range of products, including novel topoisomerase I inhibitors and oral c-Met highly selective inhibitors. Through its research and development efforts, Haihe Biopharma seeks to enhance health outcomes and the quality of research for its customers, providing effective solutions in the fight against cancer.

Yunhu Health

Series A in 2018
Yunhu Health, also known as Hangzhou Yunhu Network Technology Co., Ltd., is a Chinese company established in 2017 that specializes in mobile medical testing services. The company operates a comprehensive platform offering pregnancy, genetic, and male pre-pregnancy chromosome testing, along with various health management services. Utilizing a self-built cold chain logistics system, Yunhu Health efficiently transports inspection samples to laboratories for analysis, ensuring that test results are promptly uploaded to its cloud-based platform. This allows customers to easily access and review their results online. Additionally, the platform provides value-added services such as interpretation of inspection reports and recommendations for disease diagnosis and treatment, enhancing the diagnostic capabilities of primary medical institutions across China.

Yuchen Guangyi

Series A in 2018
Yuchen Guangyi is a high-tech enterprise integrating research, development, production and sales of a new biomedical system.

HC Scientific

Series A in 2018
HC Scientific (Chengdu) L.L.C., established in 2016, is a national high-tech enterprise focused on developing intelligent solutions in life technology. The company aims to empower life sciences through innovative products, including genetic testing instruments, reagents, and software, primarily used in clinical molecular diagnostics, health gene testing, and agricultural molecular breeding. HC Scientific is committed to autonomous research and development of intellectual property and is recognized for its contributions to China's new economy development initiatives. The organization employs a team of experts, including returning PhDs and professors, who have developed advanced life science technology platforms. Through its diverse product pipeline, HC Scientific streamlines complex tasks for practitioners in the life science field, thereby creating substantial value for its partners and contributing to significant national and provincial scientific and technological projects.

Sirius Therapeutics

Sirius Therapeutics is a biotechnology company specializing in the development of RNA interference (RNAi) therapies. It focuses on treating chronic cardiovascular diseases, providing innovative solutions for both physicians and patients.

PAQ Therapeutics

PAQ Therapeutics is a biotechnology company focused on innovating health restoration and disease treatment through the process of autophagy, which is the body's natural mechanism for cellular degradation. The company is developing a unique class of small-molecule degraders utilizing autophagosome-tethering compound technology. This approach allows for the binding of various substrates to the autophagy pathway, thereby enabling the creation of targeted therapies. By harnessing this mechanism, PAQ Therapeutics aims to provide solutions for serious diseases that currently have limited therapeutic options available to patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.